Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy

Michela Tinelli M*, Aine Roddy, Martin Knapp, Celso Arango, Maria Andreina Mendez, James Cusack, Declan Murphy, Roberto Canitano, Bethany Oakley, Vinciane Quoidbach

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children’s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.

Original languageEnglish
JournalJournal of Autism and Developmental Disorders
Publication statusAccepted/In press - 2023


  • Autism
  • Children
  • Cost-effectiveness
  • Epilepsy
  • Family impacts
  • Healthcare expenditure


Dive into the research topics of 'Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy'. Together they form a unique fingerprint.

Cite this